Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073541
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2003-11-24
Brief Title:
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
An Open-Label Phase II Study in Subjects With Recurrent EGFR-Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
EMD 72000 is an experimental biological drug Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells The factor is called epidermal growth factor receptor or EGFR One type of cancer which frequently contains EGFR is ovarian cancer This study will test the safety and effects of EMD 72000 in subjects with EGFR-positive recurrent ovarian cancer following standard treatment that has failed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None